<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous adnexal tumors&lt;sup&gt;[1-17]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous adnexal tumors<sup>[1-17]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Cutaneous adnexal tumors<sup>[1-17]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1">Sweat gland tumors (benign)</td> <td class="subtitle1">Derivation</td> <td class="subtitle1">Genetic abnormalities</td> </tr> <tr> <td>Poroma (classic poroma, hidroacanthoma simplex, dermal duct tumor)</td> <td>Eccrine or apocrine</td> <td><em>YAP1</em> fusion, <em>HRAS</em> mutation, LOH in <em>APC</em></td> </tr> <tr> <td>Hidradenoma</td> <td>Eccrine or apocrine</td> <td>MAML2, CRCT1, CRTC3 fusions</td> </tr> <tr> <td>Hidradenoma papilliferum</td> <td>Anogenital apocrine</td> <td><em>PIK3CA</em> and <em>AKT1</em> mutation</td> </tr> <tr> <td>Spiradenoma/cylindroma</td> <td>Eccrine or apocrine</td> <td><em>CYLD</em> mutation/LOH; t(6;9) <em>MYB-NFIB</em>, <em>ALPK1</em> mutation (spiradenoma), <em>DNMT3A</em> mutation (cylindroma)</td> </tr> <tr> <td>Mixed tumor</td> <td>Sweat duct ± follicular</td> <td><em>PLAG1</em>, <em>EWSR1 fusions</em>; <em>HMGA2</em> fusions in salivary mixed tumors</td> </tr> <tr> <td>Myoepithelioma</td> <td>Eccrine or apocrine</td> <td><em>EWSR1</em>, <em>FUS</em> fusions</td> </tr> <tr> <td>Syringofibroadenoma</td> <td>Eccrine</td> <td> </td> </tr> <tr> <td>Syringoma</td> <td>Eccrine or apocrine</td> <td> </td> </tr> <tr> <td>Syringocystadenoma papilliferum</td> <td>Apocrine</td> <td><em>RAS</em>, <em>BRAF</em> mutation; 9p21 deletion; 9q22 LOH</td> </tr> <tr> <td>Tubular/papillary adenoma</td> <td>Eccrine or apocrine</td> <td><em>BRAF</em> V600E, <em>KRAS</em></td> </tr> <tr> <td class="subtitle1">Sweat gland tumors (malignant)</td> <td class="subtitle1">Derivation</td> <td class="subtitle1">Genetic abnormalities</td> </tr> <tr> <td>Porocarcinoma</td> <td>Eccrine or apocrine</td> <td><em>YAP1</em>, <em>MAML2</em>, <em>NUTM1</em> fusions; <em>EGFR</em>, <em>HRAS</em>, <em>TP53</em>, <em>RB1</em>, <em>ATM</em>, <em>ARID1A</em>, <em>CDKN2A</em>, <em>PIK3CA</em> mutations</td> </tr> <tr> <td>(Aggressive) digital papillary adenocarcinoma</td> <td>Eccrine or apocrine</td> <td><em>BRAF</em> mutation, <em>FGFR2</em> overexpression</td> </tr> <tr> <td>Adenoid cystic carcinoma</td> <td>Eccrine or apocrine</td> <td>t(6;9) <em>MYB-NFIB</em>, <em>MYBL1</em> rearrangements</td> </tr> <tr> <td>Apocrine adenocarcinoma</td> <td>Apocrine</td> <td> </td> </tr> <tr> <td>Syringomatous carcinoma</td> <td>Eccrine or apocrine</td> <td> </td> </tr> <tr> <td>Hidradenocarcinoma</td> <td>Eccrine or apocrine</td> <td><em>MAML2</em> fusion; <em>TP53</em> mutation</td> </tr> <tr> <td>Malignant mixed tumor</td> <td>Eccrine or apocrine</td> <td><em>PHF1-TFE3</em> fusion (1 case)</td> </tr> <tr> <td>Cylindrocarcinoma/spiradenocarcinoma</td> <td>Eccrine or apocrine</td> <td><em>CYLD</em> mutation/LOH, <em>ALPK1</em> mutation, <em>TP53</em> mutation</td> </tr> <tr> <td>Endocrine mucin-producing sweat gland carcinoma/mucinous carcinoma</td> <td>Eccrine or apocrine</td> <td> </td> </tr> <tr> <td>Microcystic adnexal carcinoma</td> <td>Sweat duct and follicular</td> <td><em>TP53</em>, <em>JAK1</em> mutations</td> </tr> <tr> <td>Extramammary Paget disease</td> <td>Multiple possibilities</td> <td><em>PIK3CA</em> mutation; Chr 19 and X amplification; 10q loss; <em>ERBB2</em> mutation</td> </tr> <tr> <td>Cutaneous (mammary analog) secretory carcinoma</td> <td>Apocrine (possibly eccrine)</td> <td><em>ETV6-NTRK3</em> fusion</td> </tr> <tr> <td>Cutaneous cribriform carcinoma</td> <td>Apocrine</td> <td> </td> </tr> <tr> <td class="subtitle1">Follicular and sebaceous tumors (benign)</td> <td class="subtitle1">Derivation</td> <td class="subtitle1">Genetic abnormalities</td> </tr> <tr> <td>Trichoblastoma/trichoepithelioma</td> <td>Follicular</td> <td><em>CTNNB1</em>, <em>CYLD</em>, and <em>PTCH1</em> mutation</td> </tr> <tr> <td>Trichofolliculoma</td> <td>Follicular</td> <td> </td> </tr> <tr> <td>Panfolliculoma</td> <td>Follicular</td> <td> </td> </tr> <tr> <td>Proliferating follicular-cystic acanthoma (proliferating pilar tumor)</td> <td>Follicular (outer root sheath)</td> <td><em>PIK3CA</em> and <em>ALPK1</em> mutation</td> </tr> <tr> <td>Trichilemmoma</td> <td>Follicular (outer root sheath)</td> <td><em>HRAS</em>, <em>PTEN</em> mutation</td> </tr> <tr> <td>Trichoadenoma</td> <td>Follicular (infundibulum)</td> <td> </td> </tr> <tr> <td>Tumor of the follicular infundibulum</td> <td>Follicular (isthmus)</td> <td> </td> </tr> <tr> <td>Pilar sheath acanthoma</td> <td>Follicular (isthmus/infundibulum)</td> <td> </td> </tr> <tr> <td>Pilomatricoma</td> <td>Follicular (matrix)</td> <td><em>CTNNB1</em> mutation; <em>PLCD1</em> (familial pilomatricoma); trisomy 18</td> </tr> <tr> <td>Sebaceous adenoma</td> <td>Sebaceous gland</td> <td><em>LEF1</em>, MLH1, <em>MSH2</em>, <em>MSH6</em>, <em>MUTYH</em>, <em>RAS</em>, <em>TP53</em>, <em>CDKN2A</em>, <em>EGFR</em>, <em>FAT2</em>, <em>CACNA1S</em>, <em>KMT2D</em>, and <em>CTNNB1</em> mutation</td> </tr> <tr> <td>Sebaceoma</td> <td>Sebaceous gland</td> <td><em>LEF1</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em> mutation</td> </tr> <tr> <td>Fibrofolliculoma/trichodiscoma</td> <td>Sebaceous mantle</td> <td><em>FLCN</em> mutation</td> </tr> <tr> <td class="subtitle1">Follicular and sebaceous tumors (malignant)</td> <td class="subtitle1">Derivation</td> <td class="subtitle1">Genetic abnormalities</td> </tr> <tr> <td>Trichoblastic carcinoma</td> <td>Follicular</td> <td><em>TP53</em>, <em>CDKN2A</em> mutation</td> </tr> <tr> <td>Trichilemmal carcinoma</td> <td>Follicular (outer root sheath)</td> <td><em>FGFR3</em> and <em>ROS1</em> fusions); T<em>P53</em>, <em>NF1</em>, <em>NRAS</em> mutation; <em>TOP1</em> amplification and <em>PTEN</em> deletion</td> </tr> <tr> <td>Pilomatrix (matrical) carcinoma</td> <td>Follicular (matrix)</td> <td><em>CTNNB1</em> mutation</td> </tr> <tr> <td>Sebaceous carcinoma</td> <td>Sebaceous</td> <td><em>ZNF750</em>, <em>TP53</em>, <em>RREB1</em>, <em>RAS</em>, <em>NOTCH</em>, <em>FAT3</em>, <em>KMT2D</em>, <em>LEF1</em>, <em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, <em>MUTYH</em> mutation</td> </tr> </tbody></table></div><div class="graphic_footnotes">LOH: loss of heterozygosity.</div><div class="graphic_reference">References:
<ol>
<li>Harms PW, Hovelson DH, Cani AK, et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol 2016; 51:25.</li>
<li>Fehr A, Kovács A, Löning T, et al. The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol 2011; 224:322.</li>
<li>Shen AS, Peterhof E, Kind P, et al. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum. Hum Pathol 2015; 46:272.</li>
<li>Pfarr N, Sinn HP, Klauschen F, et al. Mutations in genes encoding PI3K-AKT and MAPK signaling define anogenital papillary hidradenoma. Genes Chromosomes Cancer 2016; 55:113.</li>
<li>Konstantinova AM, Vanecek T, Martinek P, et al. Molecular alterations in lesions of anogenital mammary-like glands and their mammary counterparts including hidradenoma papilliferum, intraductal papilloma, fibroadenoma and phyllodes tumor. Ann Diagn Pathol 2017; 28:12.</li>
<li>Behboudi A, Winnes M, Gorunova L, et al. Clear cell hidradenoma of the skin-a third tumor type with a t(11;19)--associated TORC1-MAML2 gene fusion. Genes Chromosomes Cancer 2005; 43:202.</li>
<li>Liau JY, Tsai JH, Huang WC, et al. BRAF and KRAS mutations in tubular apocrine adenoma and papillary eccrine adenoma of the skin. Hum Pathol 2018; 73:59.</li>
<li>North JP, McCalmont TH, Fehr A, et al. Detection of MYB Alterations and Other Immunohistochemical Markers in Primary Cutaneous Adenoid Cystic Carcinoma. Am J Surg Pathol 2015; 39:1347.</li>
<li>Sekine S, Kiyono T, Ryo E, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest 2019; 130:3827.</li>
<li>Nordmann TM, Messerli-Odermatt O, Meier L, et al. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget's disease. Oncotarget 2019; 10:6647.</li>
<li>Rashid M, van der Horst M, Mentzel T, et al. ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma. Nat Commun 2019; 10:2213.</li>
<li>Bahrami A, Dalton JD, Krane JF, Fletcher CD. A subset of cutaneous and soft tissue mixed tumors are genetically linked to their salivary gland counterpart. Genes Chromosomes Cancer 2012; 51:140.</li>
<li>Antonescu CR, Zhang L, Shao SY, et al. Frequent PLAG1 gene rearrangements in skin and soft tissue myoepithelioma with ductal differentiation. Genes Chromosomes Cancer 2013; 52:675.</li>
<li>Surowy HM, Giesen AK, Otte J, et al. Gene expression profiling in aggressive digital papillary adenocarcinoma sheds light on the architecture of a rare sweat gland carcinoma. Br J Dermatol 2019; 180:1150.</li>
<li>Kyrpychova L, Vanecek T, Grossmann P, et al. Small Subset of Adenoid Cystic Carcinoma of the Skin Is Associated With Alterations of the MYBL1 Gene Similar to Their Extracutaneous Counterparts. Am J Dermatopathol 2018; 40:721.</li>
<li>Chan MP, Plouffe KR, Liu CJ, et al. Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas. Mod Pathol 2019.</li>
<li>North JP, Golovato J, Vaske CJ, et al. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun 2018; 9:1894.</li>
</ol></div><div id="graphicVersion">Graphic 98212 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
